Drug Trial Radar · NCT05832151
A Study to Evaluate the Efficacy and Safety of CIN-102 (Deudomperidone) in Adults With Diabetic Gastroparesis
Last checked: Nov 19, 2026Latest source record: Nov 5, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
382
Actual
Start
Mar 27, 2023
Primary completion
Nov 14, 2025
Study completion Dec 12, 2025
Sponsor
- Lead sponsor
- CinDome Pharma, Inc.Industry
- Sponsor type
- Industry
- First posted
- Apr 27, 2023
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Quadruple (participant, care provider, investigator, outcomes assessor)
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The goal of this clinical trial is to evaluate if the study drug CIN-102 (deudomperidone) can help reduce the symptoms associated with diabetic gastroparesis in adult patients. The main questions it aims to answer are: * To evaluate the efficacy of CIN-102 on symptoms of gastroparesis when given to patients with diabetic gastroparesis compared to a placebo * To evaluate the safety and tolerability of CIN-102 when given to patients with diabetic gastroparesis compared to a placebo Participants will go through the following schedule: * Screening period (1-2 visits) * Lead-in period (1 visit) * Will complete a Gastric Emptying Breath Test (GEBT) * Will complete daily diary and other Patient Reported Outcomes (PROs) as described in the protocol to assess eligibility for continued study participation * 12-week treatment period (7 visits) * Study drug taken twice daily by mouth * Will complete daily diaries and other PROs as described in protocol * 1 week follow-up (1 visit) Researchers will compare the effects of the following treatments: * Drug- CIN-102 Dose 15 mg or 10 mg * Drug- Placebo
Conditions
- Diabetic Gastroparesis
Interventions
CIN-102 Dose 15mg or 10mgDrug
2 capsules twice daily for 12 weeks
PlaceboDrug
2 capsules twice daily for 12 weeks
Primary outcomes
What the sponsor says the trial is designed to measure.
- Effect of CIN-102 to significantly decrease gastroparesis-related symptoms as compared to baseline based on the composite of the average ANMS GCSI-DD Nausea Sub-Scale and Vomiting ScoresTime frame: Over the last 2 weeks of the 12-week Treatment Period as compared to baseline
Locations
100 sites in 1 country. Site status is shown where the registry gives one.
Digestive Health Specialists of the Southeast
Dothan, Alabama
G & L Research, LLC
Foley, Alabama
Clinical Research Associates, LLC
Huntsville, Alabama
Phoenix Medical Research Institute, LLC
Peoria, Arizona
Onyx Clinical Research
Phoenix, Arizona
Del Sol Research Management, LLC
Tucson, Arizona
Preferred Research Partners, Inc.
Little Rock, Arkansas
Applied Research Center of Arkansas
Little Rock, Arkansas
Arkansas Gastroenterology - North Little Rock
North Little Rock, Arkansas
Alliance Research Institute - Bell Gardens
Bell Gardens, California
Hope Clinical Research LLC
Canoga Park, California
Alliance Research Institute, LLC
Canoga Park, California
Erick H. Alayo Medical Corporation
Chula Vista, California
GW Research Inc.
Chula Vista, California
Kindred Medical Institute for Clinical Trials, LLC
Corona, California
New Hope Research Development
Corona, California
Aurora Care Clinic
Costa Mesa, California
Paragon Rx Clinical
Garden Grove, California
Valley View Wellness and Medical Center - VVCRD
Garden Grove, California
Torrance Clinical Research Institute Inc.
Lomita, California
Angel City Research
Los Angeles, California
Facey Medical Research
Mission Hills, California
Millennium Clinical Trials
Thousand Oaks, California
Innovative Research of West Florida
Clearwater, Florida
USA and International Research Inc.
Doral, Florida
Advanced Medical Research Group
Hollywood, Florida
Nature Coast Clinical Research
Inverness, Florida
ClinCloud LLC
Maitland, Florida
A+ Research Inc
Miami, Florida
International Research Associates LLC - Breton
Miami, Florida
Advanced Research Institute Inc
New Port Richey, Florida
Gastroenterology of Greater Orlando
Orange City, Florida
Tandem Clinical Research - Viera
Viera, Florida
Summit Clinical Research, LLC
Athens, Georgia
Atlanta Center for Gastroenterology P.C.
Decatur, Georgia
Medisphere Medical Research Center
Evansville, Indiana
Lutheran Medical Group
Fort Wayne, Indiana
University of Kansas Medical Center (KUMC)
Kansas City, Kansas
DelRicht Clinical Research - Overland Park
Overland Park, Kansas
Kansas Medical Clinic, P.A.
Topeka, Kansas
Showing 40 of 100 sites, US sites first. The full list is on the registry record.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.